FDA Acceptance of Auransa's IND Application for AU409 for Treatment of Patients with Hepatocellular Carcinoma

First compound to enter clinical trial stage from a pipeline of research programs based upon Auransa’s proprietary AI platform

Previous
Previous

USC Norris collaborates with Auransa on clinical trial of new targeted treatment for liver cancer and other solid tumors

Next
Next

POLARISqb and Auransa Announce Promising Results for Triple Negative Breast Cancer using Quantum Computing and AI